The effect of post-Brexit status on clinical trial logistics
One year on from Brexit, Clinical Trials Arena talks to Oximio about the impact of the trade agreement on clinical…

Lack of access to vaccines leads to 1.5 million preventable deaths each year[1]. In Africa alone, approximately one in five…
Expanded access programs (EAPs), have been in and out of the pharmaceutical spotlight since their inception back in the late…
Most advanced therapy medicinal products (ATMPs, also known as cell and gene therapies) address the clinical needs of “orphan” diseases…
No one has ever said that running clinical trials is easy. Rather, studies are arguably increasing in complexity due to…
The last 12 months were full of challenges for trial sponsors and the clinical trials market saw dynamic change when…
Clinical trial services provider, Oximio, announced in March that Peter Szabados has been appointed as the Chief Operating Officer (COO),…
The global clinical trial services provider The SMO Group announced earlier this year that the company will begin operating under…
Transformation is an overused word in the modern business lexicon, so it’s refreshing to hear a business leader, in the midst of…
Founded in 2004, the SMO Group has a strong heritage in clinical trial logistics. Now, it is entering the next…